hVIVO plc (LON:HVO – Get Free Report)’s stock price traded up 10% on Monday . The company traded as high as GBX 22 ($0.27) and last traded at GBX 21.25 ($0.26). 7,804,669 shares changed hands during mid-day trading, an increase of 164% from the average session volume of 2,961,263 shares. The stock had previously closed at GBX 19.33 ($0.24).
hVIVO Price Performance
The stock has a 50 day moving average of GBX 20.01 and a two-hundred day moving average of GBX 25.58. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The firm has a market capitalization of £129.27 million, a P/E ratio of 633.33 and a beta of 0.97.
About hVIVO
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Read More
- Five stocks we like better than hVIVO
- Where Do I Find 52-Week Highs and Lows?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- What Are Dividend Champions? How to Invest in the Champions
- 3 Steel Stocks Soaring After Tariff Announcements
- Airline Stocks – Top Airline Stocks to Buy Now
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
